Bausch Health Companies Inc. held its first sales and earnings call Aug. 7 after transitioning to the new name from the tarnished Valeant Pharmaceuticals. The company, operating also under new leadership and a new ticker symbol, continues to show slow steady progress, reporting organic sales growth in the second quarter, the second consecutive quarter of growth, even though revenues declined 5% to $2.12bn including divestitures.
Investors reacted favorably to the announcement with the stock closing up 4.5% to $23.52. The company unveiled the new corporate name and ticker symbol BHC during its first quarter earnings call in May
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
